Company Profile: QT Imaging Holdings, Inc. (QTI)
Background
QT Imaging Holdings, Inc. is a medical device company specializing in the research, development, and commercialization of body imaging systems utilizing low-frequency sound waves. Founded in 2012 and headquartered in Novato, California, the company aims to enhance global health outcomes by providing safe, accessible, and cost-effective breast imaging solutions. Their flagship product, the QT Breast Acoustic CT™ Scanner, offers non-ionizing, high-resolution 3D imaging without the use of radiation, compression, or contrast agents.
Key Strategic Focus
QT Imaging's strategic focus centers on transforming breast health management through innovative imaging technologies. The company emphasizes:
- Core Objectives: Delivering precision imaging solutions that improve diagnostic accuracy and patient comfort.
- Areas of Specialization: Breast imaging technologies, particularly for women with dense breast tissue, a demographic that comprises approximately 40% of women in the U.S.
- Key Technologies Utilized: Quantitative Transmission (QT) ultrasound, advanced image reconstruction software, and AI-driven clinical decision support systems.
- Primary Markets Targeted: Healthcare providers, radiologists, and patients globally, with a focus on underserved regions and mobile screening settings.
Financials and Funding
As of April 25, 2026, QT Imaging Holdings, Inc. (NASDAQ: QTI) has a market capitalization of approximately $62 million. In 2025, the company reported revenues of $18.93 million, marking a 287.89% increase from the previous year. Despite this growth, the company reported a net loss of $21.08 million for the same period.
In the second quarter of 2025, QT Imaging secured $700,000 in net proceeds from two Private Investment in Public Entity (PIPE) investments, with contributions from board members and external investors.
Pipeline Development
QT Imaging's primary product, the QT Breast Acoustic CT™ Scanner, is FDA-cleared and commercially available. The company continues to enhance its offerings by integrating AI-driven clinical decision support and developing a cloud-based image analytics platform to provide comprehensive breast health management solutions.
Technological Platform and Innovation
QT Imaging distinguishes itself through several innovative technological platforms:
- Proprietary Technologies: The QT Breast Acoustic CT™ Scanner employs low-frequency sound waves to produce high-resolution 3D breast images without radiation or contrast agents.
- Significant Scientific Methods: The integration of AI algorithms for lesion classification and the development of a cloud-based image analytics platform for enhanced diagnostic support.
Leadership Team
The executive team at QT Imaging Holdings includes:
- Dr. Raluca Dinu, Ph.D.: Chief Executive Officer and Director.
- Anastas Budagov: Chief Financial Officer.
- Steve Choate: Chief Operating Officer.
- Dr. Bilal Malik, Ph.D.: Chief Science Officer.
- Nasser C. Pirshafiey, M.B.A.: Chief Product Officer.
- Dr. Elaine Iuanow, M.D.: Chief Medical Officer.
- Satrajit Misra: Chief Commercial Officer.
These leaders bring diverse expertise in medical technology, finance, operations, science, product development, and commercialization to drive the company's mission forward.
Market Insights and Competitor Analysis
The medical imaging industry, particularly breast imaging, is experiencing significant growth due to increasing awareness of breast health and advancements in imaging technologies. QT Imaging's focus on non-ionizing, high-resolution 3D imaging positions it favorably in a market that values patient safety and diagnostic accuracy.
QT Imaging faces competition from companies such as Alpha Tau Medical (NASDAQ: DRTS), NeuroPace (NASDAQ: NPCE), Avanos Medical (NYSE: AVNS), OrthoPediatrics (NASDAQ: KIDS), and Brainsway (NASDAQ: BWAY). These competitors operate in the broader medical equipment sector, with varying focuses and technologies. For instance, Alpha Tau Medical specializes in cancer treatment technologies, while NeuroPace focuses on neuromodulation therapies. QT Imaging's unique value proposition lies in its specialized breast imaging solutions.
Strategic Collaborations and Partnerships
QT Imaging has established a collaboration with Olea Medical S.A.S for the development of the QTI Imaging-Olea Viewer, aiming to integrate multimodal breast imaging within a single user interface.
Operational Insights
QT Imaging's focus on non-ionizing, high-resolution 3D imaging without the use of radiation or contrast agents differentiates it from competitors. This approach addresses key clinical gaps, particularly for women with dense breast tissue, a demographic that comprises approximately 40% of women in the U.S.
Strategic Opportunities and Future Directions
QT Imaging plans to expand its product offerings by integrating AI-driven clinical decision support and developing a cloud-based image analytics platform. These initiatives aim to enhance diagnostic accuracy, improve patient outcomes, and increase market penetration. The company's focus on underserved regions and mobile screening settings presents opportunities for growth and impact.
